Mostrar el registro sencillo del documento

dc.creatorAkula, Shaw M.
dc.creatorAbrams, Stephen L.
dc.creatorSteelman, Linda S.
dc.creatorCandido, Saverio
dc.creatorLibra, Massimo
dc.creatorLerpiriyapong, Kvin
dc.creatorCocco, Lucio
dc.creatorRamazzotti, Giulia
dc.creatorRatti, Stefano
dc.creatorFollo, Matilde Y.
dc.creatorMartelli, Alberto M.
dc.creatorBlalock, William L.
dc.creatorPiazzi, Manuela
dc.creatorMontalto, Giuseppe
dc.creatorCervello, Melchiorre
dc.creatorNotarbartolo, Monica
dc.creatorBasecke, Jorg
dc.creatorMcCubrey, James A.
dc.date.accessioned2020-07-22T15:45:36Z
dc.date.available2020-07-22T15:45:36Z
dc.date.created2020
dc.identifier.issn2212-4926spa
dc.identifier.otherhttps://doi.org/10.1016/j.jbior.2020.100739spa
dc.identifier.urihttp://hdl.handle.net/20.500.12010/10936
dc.description.abstractThe COVID-19 pandemic has put a serious strain on health treatments as well at the economies of many nations. Unfortunately, there is not currently available vaccine for SARS-Cov-2/COVID-19. Various types of patients have delayed treatment or even routine check-ups and we are adapting to a virtual world. In many cases, surgeries are delayed unless they are essential. This is also true with regards to cancer treatments and screening. Interestingly, some existing drugs and nutraceuticals have been screened for their effects on COVID-19. Certain FDA approved drugs, vitamin, natural products and trace minerals may be repurposed to treat or improve the prevention of COVID-19 infections and disease progression. This review article will summarize how the treatments of various cancer patients has changed during the COVID-19 era as well as discuss the promise of some existing drugs and other agents to be repurposed to treat this disease.spa
dc.format.extent11 páginasspa
dc.format.mimetypeimage/jepgspa
dc.publisherScience Directeng
dc.sourcereponame:Expeditio Repositorio Institucional UJTLspa
dc.sourceinstname:Universidad de Bogotá Jorge Tadeo Lozanospa
dc.subjectCOVID-19spa
dc.subjectCancerspa
dc.subjectNatural productsspa
dc.subjectNutraceuticalsspa
dc.subjectRepurposing approved drugsspa
dc.titleCancer therapy and treatments during COVID-19 eraspa
dc.type.localArtículospa
dc.subject.lembSíndrome respiratorio agudo gravespa
dc.subject.lembCOVID-19spa
dc.subject.lembSARS-CoV-2spa
dc.subject.lembCoronavirusspa
dc.rights.accessrightsinfo:eu-repo/semantics/openAccessspa
dc.type.hasversioninfo:eu-repo/semantics/acceptedVersionspa
dc.identifier.doihttps://doi.org/10.1016/j.jbior.2020.100739spa


Archivos en el documento

Thumbnail
Thumbnail

Este documento aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del documento